Alain FISCHER
Imagine Institute · Assistance Publique - Hôpitaux de Paris
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alain FISCHER as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:47 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02954640 · Evaluation of the Efficacy of the Sequencing Method by Gene-panelImagine Institute · completed · Primary Immuno-Deficiencies · study chair
- N/ANCT02909244 · Study of Gut Microbiota in Primary Immune Deficiency, Possibly Associated With Inflammatory Bowel DiseaseImagine Institute · completed · Primary Immune Deficiencies · study chair
- Ph1/Ph2NCT02472054 · Treatment of Familiar LymphohistiocytosisAssistance Publique - Hôpitaux de Paris · completed · Hemophagocytic Lymphohistiocytosis (HLH) · study director
- Ph1/Ph2NCT01410019 · Gene Therapy for X-linked Severe Combined ImmunodeficiencyAssistance Publique - Hôpitaux de Paris · completed · X-linked Severe Combined Immunodeficiency · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:47 UTC. The ranking covers the 200 most relevant of 161 PubMed records, and a shared surname and initials can bring in a namesake. All 161 on PubMed
- 1,889 citationsRCR 35.9
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.J Clin Invest · 20081,483 citationsRCR 30.5
- Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.N Engl J Med · 20191,211 citationsRCR 60.4
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.Lancet Respir Med · 2016844 citationsRCR 37.4
- Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.N Engl J Med · 2002830 citationsRCR 14.9
- Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.Lancet Respir Med · 2020500 citationsRCR 29.3
- Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations.J Clin Invest · 2014466 citationsRCR 11.6
- Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.N Engl J Med · 1991328 citationsRCR 10.4
- 315 citationsRCR 8.4
- 311 citationsRCR 8.0